Emergent BioSolutions Issues Weaker FY26 Revenue Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy EBS?
Source: stocktwits
Emergent BioSolutions' stock dropped 26.49% as it crossed below the 5-day SMA, following disappointing financial results and a significant revenue guidance miss for 2026.
The company announced a revenue forecast of $720M to $760M for 2026, which is substantially below the consensus estimate of $1.16B. This news, combined with a Q4 revenue decline of approximately 24% to $148.7M and a non-GAAP EPS of -$0.43, has led to a sharp decline in stock price. Despite these setbacks, Emergent reported an improved cash position of $209.1M by the end of 2025 and authorized a $50 million stock buyback program to enhance shareholder value.
The implications of this guidance miss are significant, as it reflects ongoing operational challenges and market pressures. Investors will be closely monitoring the company's ability to execute its growth plans and manage its product portfolio effectively.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EBS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EBS
Wall Street analysts forecast EBS stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 11.100
Low
15.00
Averages
15.00
High
15.00
Current: 11.100
Low
15.00
Averages
15.00
High
15.00
About EBS
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Emergent BioSolutions Stock Drops 22% Following Decline in Q4 Revenue
- Stock Performance: Emergent Biosolutions shares have decreased by 22%.
- Revenue Decline: The drop in stock price follows a fall in revenue for the fourth quarter.
See More
Emergent BioSolutions Q4 2025 Earnings Call Highlights
- Significant Financial Improvement: Emergent BioSolutions reported total Q4 2025 revenues of $149 million, with adjusted EBITDA at $11 million and gross margin rising to 43%, indicating substantial progress in operational efficiency and cost control, thereby enhancing the foundation for future profitability.
- Strategic Investment and Growth Plans: The company plans to invest in revenue growth drivers in the MCM and naloxone segments for 2026, with total revenue expected between $720 million and $760 million, reflecting management's confidence in future market demand despite uncertainties from government shutdowns.
- Shareholder Returns and Liquidity: By the end of 2025, the company had total liquidity of $305 million, including $205 million in cash and $100 million of undrawn credit capacity, while repurchasing 3.1 million shares and authorizing a $50 million stock buyback program, demonstrating a commitment to shareholder value.
- Debt Management and Leverage Reduction: The company reduced its net leverage ratio from 3.3x in 2024 to 1.9x through a $100 million voluntary loan prepayment, reflecting ongoing efforts in financial stability and risk management, laying a solid foundation for future growth.
See More
Flutter Entertainment Reports Disappointing Q4 Results, Shares Plunge
- Disappointing Financial Results: Flutter Entertainment reported Q4 revenue of $4.74 billion, a 25% year-over-year increase, yet it fell short of the market expectation of $4.97 billion, indicating challenges in revenue growth that could impact investor confidence moving forward.
- Earnings Miss: The company posted earnings per share of $1.74, missing the consensus estimate of $1.99, reflecting pressures from rising costs and intensified market competition, which may raise concerns about future profitability among investors.
- Significant Stock Decline: In pre-market trading, Flutter's shares plummeted by 14.8% to $104.84, indicating a strong market reaction to the disappointing earnings report, which could adversely affect the company's short-term market performance.
- Uncertain Future Guidance: Flutter issued weak FY26 revenue guidance in its report, potentially diminishing market confidence in the company's growth prospects and exacerbating stock volatility risks.
See More
U.S. Stocks Decline Midway; Dell Shares Surge Over 21%
- Market Performance: U.S. stocks traded lower midway through the session, with the Nasdaq Composite falling over 1%, the Dow down 1.40% to 48,807.06, and the S&P 500 dropping 0.74% to 6,858.05, indicating overall market weakness.
- Dell's Earnings Beat: Dell Technologies Inc. (NYSE:DELL) shares surged over 21% on Friday after reporting fourth-quarter earnings of $3.89 per share, exceeding the consensus estimate of $3.53, with quarterly revenue hitting $33.38 billion, up from $23.93 billion a year ago, showcasing strong financial performance.
- Sector Dynamics: Consumer staples stocks rose by 1.3%, while financial stocks fell by 2.6%, reflecting mixed reactions across sectors that could influence investors' asset allocation strategies.
- Commodity Market Fluctuations: Oil prices increased by 2% to $66.54, gold rose by 1.1% to $5,252.30, and silver jumped 7.7% to $94.360, indicating active commodity markets and heightened demand for safe-haven assets.
See More
Emergent BioSolutions' 2026 Revenue Guidance Falls Short of Expectations
- Revenue Guidance Miss: Emergent BioSolutions announced a 2026 revenue forecast of $720M to $760M, significantly below the consensus estimate of $1.16B, resulting in a ~23% drop in stock price during Friday morning trading.
- Disappointing Financial Results: The company's Q4 results showed a year-over-year revenue decline of ~24% to $148.7M, with a non-GAAP EPS of -$0.43 compared to $0.05 in the same period last year, indicating a substantial deterioration in profitability.
- Improved Cash Position: By the end of 2025, Emergent reported cash, cash equivalents, and restricted cash of $209.1M, up from $105.6M at the end of 2024, reflecting an improvement in liquidity management despite operational challenges.
- Stock Buyback Program: The company authorized a $50 million stock repurchase program aimed at enhancing shareholder value, demonstrating management's confidence in future growth prospects despite the current financial setbacks.
See More
U.S. Stocks Drop Over 600 Points in Morning Trading
- Market Decline: U.S. stocks traded lower this morning, with the Dow Jones index falling over 600 points on Friday, a 1.25% drop to 48,879.67, indicating weakened market sentiment.
- Tech Sector Drop: Information technology stocks fell by 1.8% during Friday's trading, reflecting investor concerns about the sector's outlook, which may impact future investment decisions.
- Producer Prices Rise: U.S. producer prices increased by 0.5% month-over-month in January, surpassing market expectations of 0.3% and the revised 0.4% gain in December, indicating persistent inflationary pressures that could influence Federal Reserve policy.
- Commodity Market Fluctuations: Oil prices rose by 3.5% to $67.51, while gold increased by 1% to $5,243.90, suggesting that investors are turning to commodities for safety amid an uncertain stock market environment.
See More
Emergent BioSolutions Stock Drops 22% Following Decline in Q4 Revenue
- Stock Performance: Emergent Biosolutions shares have decreased by 22%.
- Revenue Decline: The drop in stock price follows a fall in revenue for the fourth quarter.
See More
Emergent BioSolutions Q4 2025 Earnings Call Highlights
- Significant Financial Improvement: Emergent BioSolutions reported total Q4 2025 revenues of $149 million, with adjusted EBITDA at $11 million and gross margin rising to 43%, indicating substantial progress in operational efficiency and cost control, thereby enhancing the foundation for future profitability.
- Strategic Investment and Growth Plans: The company plans to invest in revenue growth drivers in the MCM and naloxone segments for 2026, with total revenue expected between $720 million and $760 million, reflecting management's confidence in future market demand despite uncertainties from government shutdowns.
- Shareholder Returns and Liquidity: By the end of 2025, the company had total liquidity of $305 million, including $205 million in cash and $100 million of undrawn credit capacity, while repurchasing 3.1 million shares and authorizing a $50 million stock buyback program, demonstrating a commitment to shareholder value.
- Debt Management and Leverage Reduction: The company reduced its net leverage ratio from 3.3x in 2024 to 1.9x through a $100 million voluntary loan prepayment, reflecting ongoing efforts in financial stability and risk management, laying a solid foundation for future growth.
See More
Flutter Entertainment Reports Disappointing Q4 Results, Shares Plunge
- Disappointing Financial Results: Flutter Entertainment reported Q4 revenue of $4.74 billion, a 25% year-over-year increase, yet it fell short of the market expectation of $4.97 billion, indicating challenges in revenue growth that could impact investor confidence moving forward.
- Earnings Miss: The company posted earnings per share of $1.74, missing the consensus estimate of $1.99, reflecting pressures from rising costs and intensified market competition, which may raise concerns about future profitability among investors.
- Significant Stock Decline: In pre-market trading, Flutter's shares plummeted by 14.8% to $104.84, indicating a strong market reaction to the disappointing earnings report, which could adversely affect the company's short-term market performance.
- Uncertain Future Guidance: Flutter issued weak FY26 revenue guidance in its report, potentially diminishing market confidence in the company's growth prospects and exacerbating stock volatility risks.
See More
U.S. Stocks Decline Midway; Dell Shares Surge Over 21%
- Market Performance: U.S. stocks traded lower midway through the session, with the Nasdaq Composite falling over 1%, the Dow down 1.40% to 48,807.06, and the S&P 500 dropping 0.74% to 6,858.05, indicating overall market weakness.
- Dell's Earnings Beat: Dell Technologies Inc. (NYSE:DELL) shares surged over 21% on Friday after reporting fourth-quarter earnings of $3.89 per share, exceeding the consensus estimate of $3.53, with quarterly revenue hitting $33.38 billion, up from $23.93 billion a year ago, showcasing strong financial performance.
- Sector Dynamics: Consumer staples stocks rose by 1.3%, while financial stocks fell by 2.6%, reflecting mixed reactions across sectors that could influence investors' asset allocation strategies.
- Commodity Market Fluctuations: Oil prices increased by 2% to $66.54, gold rose by 1.1% to $5,252.30, and silver jumped 7.7% to $94.360, indicating active commodity markets and heightened demand for safe-haven assets.
See More
Emergent BioSolutions' 2026 Revenue Guidance Falls Short of Expectations
- Revenue Guidance Miss: Emergent BioSolutions announced a 2026 revenue forecast of $720M to $760M, significantly below the consensus estimate of $1.16B, resulting in a ~23% drop in stock price during Friday morning trading.
- Disappointing Financial Results: The company's Q4 results showed a year-over-year revenue decline of ~24% to $148.7M, with a non-GAAP EPS of -$0.43 compared to $0.05 in the same period last year, indicating a substantial deterioration in profitability.
- Improved Cash Position: By the end of 2025, Emergent reported cash, cash equivalents, and restricted cash of $209.1M, up from $105.6M at the end of 2024, reflecting an improvement in liquidity management despite operational challenges.
- Stock Buyback Program: The company authorized a $50 million stock repurchase program aimed at enhancing shareholder value, demonstrating management's confidence in future growth prospects despite the current financial setbacks.
See More
U.S. Stocks Drop Over 600 Points in Morning Trading
- Market Decline: U.S. stocks traded lower this morning, with the Dow Jones index falling over 600 points on Friday, a 1.25% drop to 48,879.67, indicating weakened market sentiment.
- Tech Sector Drop: Information technology stocks fell by 1.8% during Friday's trading, reflecting investor concerns about the sector's outlook, which may impact future investment decisions.
- Producer Prices Rise: U.S. producer prices increased by 0.5% month-over-month in January, surpassing market expectations of 0.3% and the revised 0.4% gain in December, indicating persistent inflationary pressures that could influence Federal Reserve policy.
- Commodity Market Fluctuations: Oil prices rose by 3.5% to $67.51, while gold increased by 1% to $5,243.90, suggesting that investors are turning to commodities for safety amid an uncertain stock market environment.
See More
